{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:32:00Z","timestamp":1790065920615,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40257-022-00725-9","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T08:02:49Z","timestamp":1662537769000},"page":"905-914","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-1433","authenticated-orcid":false,"given":"Klasiena","family":"Bouwman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Dudink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrooz Z.","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette M.","family":"Prens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allard R. J. V.","family":"Vossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey R.","family":"van Straalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessel H.","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"issue":"1","key":"725_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"725_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40265-015-0516-5","volume":"76","author":"IE Deckers","year":"2016","unstructured":"Deckers IE, Prens EP. An update on medical treatment options for hidradenitis suppurativa. Drugs. 2016;76(2):215\u201329.","journal-title":"Drugs"},{"issue":"4","key":"725_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juh\u00e1sz I, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"725_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000503605","volume":"237","author":"AJ Hendricks","year":"2021","unstructured":"Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology. 2021;237(1):81\u201396.","journal-title":"Dermatology"},{"issue":"1","key":"725_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"725_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/ced.12655","volume":"40","author":"H Naasan","year":"2015","unstructured":"Naasan H, Affleck A. Atypical hidradenitis suppurativa. Clin Exp Dermatol. 2015;40(8):891\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"725_CR7","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/jid.2012.472","volume":"133","author":"F Canoui-Poitrine","year":"2013","unstructured":"Canoui-Poitrine F, Le Thuaut A, Revuz JE, Viallette C, Gabison G, Poli F, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133(6):1506\u201311.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"725_CR8","doi-asserted-by":"publisher","first-page":"A150","DOI":"10.1016\/j.jaad.2015.02.616","volume":"72","author":"AS-MV Martorell-Calayud","year":"2015","unstructured":"Martorell-Calayud AS-MV, Alfaro-Rubio A, Parra-Uribe M, Garcia-Melgares ML, Pelufo C, Hueso-Gabriel L. Phenotypic heterogeneity in hidradenitis suppurativa. J Am Acad Dermatol. 2015;72(5):A150.","journal-title":"J Am Acad Dermatol"},{"key":"725_CR9","first-page":"1","volume":"14","author":"K Dudink","year":"2021","unstructured":"Dudink K, Aarts P, Ardon CB, Vossen A, Koster SBL, Van den Bosch JF, et al. Prevalence and clinical characteristics of hidradenitis suppurativa phenotypes in a large Dutch cohort. Dermatology. 2021;14:1\u20133.","journal-title":"Dermatology"},{"issue":"10","key":"725_CR10","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/sj.jid.5700289","volume":"126","author":"AM Nelson","year":"2006","unstructured":"Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol. 2006;126(10):2178\u201389.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"725_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1046\/j.1523-1747.2000.00066.x","volume":"115","author":"M Tsukada","year":"2000","unstructured":"Tsukada M, Schr\u00f6der M, Roos TC, Chandraratna RA, Reichert U, Merk HF, et al. 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol. 2000;115(2):321\u20137.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"725_CR12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1517\/14656566.6.10.1725","volume":"6","author":"CS Lee","year":"2005","unstructured":"Lee CS, Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother. 2005;6(10):1725\u201334.","journal-title":"Expert Opin Pharmacother"},{"key":"725_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/0076-6879(90)90038-3","volume":"190","author":"TI Doran","year":"1990","unstructured":"Doran TI, Shapiro SS. Retinoid effects on sebocyte proliferation. Methods Enzymol. 1990;190:334\u20138.","journal-title":"Methods Enzymol"},{"issue":"1","key":"725_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/19381980.2017.1361575","volume":"9","author":"L Lu","year":"2017","unstructured":"Lu L, Lai H, Pan Z, Hu T, Hou X, Cao K, et al. Clinical and histopathological characteristics in patients with scarring folliculitis type of acne inversa. Dermatoendocrinol. 2017;9(1): e1361575.","journal-title":"Dermatoendocrinol."},{"issue":"5 Suppl 1","key":"725_CR15","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","volume":"73","author":"HH van der Zee","year":"2015","unstructured":"van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes. J Am Acad Dermatol. 2015;73(5 Suppl 1):S23\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"725_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2340\/00015555-2513","volume":"97","author":"B Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th B, Janse IC, Blok JL, Driessen RJ, Boer J, Mekkes JR, et al. Hurley staging refined: a proposal by the dutch hidradenitis suppurativa expert group. Acta Derm Venereol. 2017;97(3):412\u20133.","journal-title":"Acta Derm Venereol"},{"key":"725_CR17","volume-title":"Dermatologic surgery, principles and practice","author":"H Hurley","year":"1989","unstructured":"Hurley H. Dermatologic surgery, principles and practice. New York: Marcel; 1989."},{"issue":"5","key":"725_CR18","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"725_CR19","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S0190-9622(96)90277-7","volume":"34","author":"GB Jemec","year":"1996","unstructured":"Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol. 1996;34(6):994\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"725_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1365-2133.2010.10071.x","volume":"164","author":"J Boer","year":"2011","unstructured":"Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164(1):170\u20135.","journal-title":"Br J Dermatol"},{"issue":"2\u20133","key":"725_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000477207","volume":"233","author":"CM Huang","year":"2017","unstructured":"Huang CM, Kirchhof MG. A new perspective on isotretinoin treatment of hidradenitis suppurativa: a retrospective chart review of patient outcomes. Dermatology. 2017;233(2\u20133):120\u20135.","journal-title":"Dermatology"},{"issue":"2","key":"725_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000182261","volume":"218","author":"A Soria","year":"2009","unstructured":"Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients\u2019 outcome assessment. Dermatology. 2009;218(2):134\u20135.","journal-title":"Dermatology"},{"issue":"4","key":"725_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/09546634.2019.1670779","volume":"32","author":"N Patel","year":"2021","unstructured":"Patel N, McKenzie SA, Harview CL, Truong AK, Shi VY, Chen L, et al. Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study. J Dermatol Treat. 2021;32(4):473\u20135.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"725_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bjd.12884","volume":"171","author":"L Matusiak","year":"2014","unstructured":"Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014;171(1):170\u20134.","journal-title":"Br J Dermatol"},{"issue":"2","key":"725_CR25","first-page":"155","volume":"150","author":"R Verdolini","year":"2015","unstructured":"Verdolini R, Simonacci F, Menon S, Pavlou P, Mannello B. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G Ital Dermatol Venereol. 2015;150(2):155\u201362.","journal-title":"G Ital Dermatol Venereol"},{"issue":"7","key":"725_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/j.1468-3083.2006.01671.x","volume":"20","author":"AM Layton","year":"2006","unstructured":"Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol. 2006;20(7):773\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"725_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjd.19863","volume":"185","author":"LM Prens","year":"2021","unstructured":"Prens LM, Bouwman K, Aarts P, Arends S, van Straalen KR, Dudink K, et al. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study. Br J Dermatol. 2021;185(1):177\u201384.","journal-title":"Br J Dermatol"},{"key":"725_CR28","unstructured":"Jones N, Marks R, Ramirez R, Rios\u2010Vargas M. 2020 census illuminates racial and ethnic composition of the country. United States Census Bureau. 2021."},{"key":"725_CR29","unstructured":"Statline.cbs.nl. CBS StatLine - Bevolking; generatie, geslacht, leeftijd en herkomstgroepering, 1 januari. 2022 [cited 2022 11 augustus]. Available from: http:\/\/statline.cbs.nl\/StatWeb\/publication\/?DM=SLNL&PA=37325&D1=0&D2=a&D3=0&D4=0&D5=a&D6=l&HDR=G2,G3&STB=G1,G5,T,G4&VW=T."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00725-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00725-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00725-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T05:42:53Z","timestamp":1665985373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00725-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00725-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"15 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The HiCARE\/HiSURE and HiScreen registries are co-funded by AbbVie Netherlands. The co-funder had no role in the design or conduct of the study, the interpretation of the data, or the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"KB, PA, JH, BA, LP, AV, and KvS report no conflicts of interest. HvdZ has been an advisory board member for AbbVie, InflaRX, Novartis and a speaker for Galderma. BH reports fees from Janssen-Cilag (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), AbbVie (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), Novartis Pharma (Advisory Boards, Consultations, Investigator Initiative Studies), UCB Pharma (Advisory Boards, Consultations), Leo Pharma (Consultations), Solenne B.V. (Investigator Initiative Studies), Celgene (Consultations, Investigator Initiative Studies), Akari therapeutics (Consultations, Investigator Initiative Studies), Philips (Consultation), Roche (Consultation), Regeneron (Consultation) and Sanofi (Consultation), which fees were paid to the institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethical committee of the University Medical Center Groningen UMCG verified that the Medical Research Involving Human Subjects Act (WMO) did not apply to this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research ethics"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\n                      \n                      A, B.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by KB, PA and KD. The first draft of the manuscript was written by KB and PA and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}